NACT followed by ICS significantly improves 3-year PFS and OS in advanced ovarian cancer compared to chemotherapy alone. Patients undergoing NACT and ICS had better outcomes than those receiving only ...

Adjuvant therapy in the treatment of biliary tract cancer (BTC): A systematic review and meta-analysis. Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type-1 ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses new data from the TRUST trial, which were ...

The optimal timing of surgery in patients with resectable advanced ovarian cancer remains controversial. Should these patients receive the standard radical surgery followed by chemotherapy, or could ...

Declining cytoreductive surgery in advanced EOC is associated with significantly poorer survival outcomes compared to those who undergo the procedure. Sociodemographic factors, including race, age, ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...

Neoadjuvant chemotherapy (NACT) is a treatment for advanced ovarian cancer – cancer at stage III or IV. It uses chemo drugs to shrink tumors before any surgery is done to remove them. NACT uses a ...